CGT Catapult has launched the Advanced Therapies Skills Training Network, designed to open career opportunities and upskill staff in advanced therapy and vaccine manufacturing in the UK.
According to a Dec. 2, 2020 press release, the Cell and Gene Therapy Catapult (CGT Catapult) has launched the Advanced Therapies Skills Training Network (ATSTN), designed to open career opportunities and upskill staff in advanced therapy and vaccine manufacturing in the United Kingdom.
The nationwide initiative, driven by industry and coordinated by the CGT Catapult, comprises dedicated online resources and national centers to upskill, and provides an opportunity for people to identify how they can enter the industry. ATSTN is funded by an award of £4.7 million (US $6.3 million) from the Department for Business, Energy & Industrial Strategy (BEIS) through UK Research and Innovation (UKRI).
“It is vital that we upskill our workforce to develop and manufacture vaccines and treatments at scale, ensuring the advanced therapy and vaccine manufacturing sectors are stronger and more resilient in the future,” said UK Business Secretary Alok Sharma, in the press release. “Backed with almost £5 million government investment, this first-of-its-kind skills network will equip people at all stages of their careers to pursue opportunities in advanced medicines and vaccine manufacturing. This will help to create highly skilled jobs across the country while putting the UK in the strongest position to respond to future pandemics.”
“One of the tasks of the government’s Vaccines Taskforce is to ensure the UK has the capabilities to respond to future health crises, and this includes scaling up our ability to manufacture safe and effective vaccines and treatments,” added Kate Bingham, chair of the Vaccines Taskforce, in the press release. “By upskilling and expanding the UK’s vaccine manufacturing industry, this new skills network will help to ensure the UK has the capacity to produce successful vaccines at scale, including for coronavirus, helping to protect the UK population for generations to come.”
“The ATSTN initiative reiterates our commitment to upskill new and existing members of the advanced therapy workforce, building on the success and impact of the ATAC apprenticeship program,” commented Matthew Durdy, CEO of CGT Catapult, in the press release. “Not only is it rewarding to work so closely with industry to deliver on this need, but it is also extremely motivating for all involved to think that this initiative is going to be the start of so many promising careers and additional job opportunities. We look forward to seeing the success stories from users of this ground-breaking platform.”
Source: CGT Catapult
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.